Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.46 |
| ▸ | ACE | P12821 | 8/20 | 0.46 |
| ▸ | CPA1 | P15085 | 6/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364320 | 0.91 | MME (0.53) | MMEACECPA1ACE2PPARA | |
| SCHEMBL3363774 | 0.82 | MME (0.51) | MMEACECPA1ACE2PPARA | |
| SCHEMBL3363766 | 0.82 | MME (0.51) | MMEACECPA1ACE2PPARA | |
| SCHEMBL3363660 | 0.81 | PPARA (0.54) | MMEACECPA1ACE2PPARA | |
| SCHEMBL3363659 | 0.80 | ACE (0.46) | MMEACECPA1ACE2MAPK1 | |
| SCHEMBL9074278 | 0.78 | ACE (0.59) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL9074287 | 0.78 | ACE (0.59) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL1374896 | 0.74 | PPARA (0.76) | ACEPPARAPPARGCTSS | |
| SCHEMBL1374891 | 0.74 | PPARA (0.76) | ACEPPARAPPARGCTSS | |
| SCHEMBL5001071 | 0.74 | PPARA (0.76) | ACEPPARAPPARGCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239268-A1 | Dipeptide derivatives | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| EP-2239268-A1 | Dipeptide derivatives | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-6992105-B2 | Dipeptide derivatives | NOVARTIS AG (CH) | 2006-01-31 | — | — | US | disclosed |
| US-20040235754-A1 | Dipeptide derivatives | NOVARTIS AG (CH) | 2004-11-25 | — | — | US | disclosed |
| US-6777443-B2 | Dipeptide derivatives | NOVARTIS AG (CH) | 2004-08-17 | — | — | US | disclosed |
| EP-1392720-A2 | DIPEPTIDE DERIVATIVES HAVING A N-TERMINAL 2-THIOACYL GROUP AS VASOPEPTIDASE INHIBITORS | Novartis AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-20020183260-A1 | Dipeptide derivatives | NOVARTIS AG (CH) | 2002-12-05 | — | — | US | disclosed |
| WO-2002092622-A2 | DIPEPTIDE DERIVATIVES HAVING A N-TERMINAL 2-THIOACYL GROUP AS VASOPEPTIDASE INHIBITORS | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183260-A1 | Dipeptide derivatives | ANPEP, ECE1, ECE2 | MME 9/4885ACE 16/4885CPA1 40/4885 |
| US-20040235754-A1 | Dipeptide derivatives | ANPEP, ECE1, ECE2 | MME 9/4885ACE 16/4885CPA1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.